🔗 Share this article

While the United States proceeds with sweeping adjustments to its immunization schedules, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by questioning COVID-19 shots throughout the global health crisis and has zeroed in on alleged fatalities after Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Program

Agency leaders had intended to announce radical changes to the childhood vaccine schedule recently, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US at odds with a large portion of the international standard with no evidence for public health gain. The announcement has been delayed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

Consolidating Power at the FDA

The acting appointment could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending certain childhood shot schedules in the US to become more in line with Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – traditionally the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

Høeg has no obvious experience in medication creation, regulation or management, which has been standard for previous leaders of the CBER. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who headed the center have had.”

CDER has an immense range of responsibilities at the FDA, the former commissioner emphasized.

“Everybody just pays attention on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and all of those need to be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the role, which manages more than 5,000 personnel. “It is a enormous management job, if you execute it properly,” the former official added.

Official Statement and Disputed Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this selection indicates more teamwork among agency officials on vaccines, a representative responded that the “inquiries stem from inaccurate assumptions”.

“Her experience is consistent with the functions of her role,” the representative explained, pointing to the months Dr. Høeg spent advising the agency head on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial expedited medication authorization process that apparently troubled her preceding directors. “How are these medications being chosen for this fast-track system? Who takes the calls?” Dr. Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards less stringent rules of most medications, aside from immunizations.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if problematic, history, critics said. She released a research paper using non-validated volunteer-provided data to estimate the incidence of myocarditis following COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the current government featured changing regulations for recently developed shots and discontinuing “optional” immunizations, she remarked after the election on a audio program. At the FDA, Dr. Høeg has reportedly suggested excluding young men from receiving COVID-19 vaccinations.

“She is an thorough ideologue who starts off with her preconceived notions and reverse-engineers to accommodate the evidence in a extremely deceptive, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined other contrarians, {like|